Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 1034 • 2013 ACR/ARHP Annual Meeting
The Part Of Function (Health assessment Questionnaire) In The SF-6D and EQ-5D Utility Measures Varies Over Time In Early Arthritis (ESPOIR cohort): Questionable Validity Of Deriving Quality Adjusted Life Years From HAQ
Cécile Gaujoux-Viala¹, Anne-Christine Rat², Kossar Hosseini³, Rene-Marc Flipo⁴, Francis Guillemin³ and Bruno Fautrel⁵, ¹EA 2415, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France, ²Université de Lorraine, Nancy, F-54000, France; Inserm, CIC-EC CIE6, Nancy, F-54000, France; CHU de Nancy, Clinical Epidemiology and Evaluation Department, Nancy, F-54000, France; CHU de Nancy, Rheumatology department, Nancy, France, ³CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁴Rheumatology, University Hospital Lille, Lille, France, ⁵Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France
Background/Purpose: There is growing emphasis on the cost-effectiveness of treating early arthritis (EA). As few studies directly record the utility measures needed for economic analyses,…
Abstract Number: 1960 • 2013 ACR/ARHP Annual Meeting
Combination Of Magnetic Resonance Imaging-Proven Osteitis With 2010 RA Classification Criteria Improves The Diagnostic Probability Of Early Rheumatoid Arthritis Whose Disease Duration Less Than 6 Months
Mami Tamai^1,2, Junko Kita³, Yoshikazu Nakashima⁴, Ayako Nishino⁴, Takahisa Suzuki⁴, Yoshiro Horai⁴, Akitomo Okada⁵, Tomohiro Koga⁶, Shin-ya Kawashiri^4,7, Naoki Iwamoto⁴, Kunihiro Ichinose⁴, Kazuhiko Arima⁷, Satoshi Yamasaki⁸, Hideki Nakamura⁴, Tomoki Origuchi⁹, Masataka Uetani¹⁰, Aya Fukushima¹⁰, Kiyoshi Aoyagi⁷, Katsumi Eguchi¹¹ and Atsushi Kawakami⁴, ¹Center for Health & Community Medicine, Nagasaki University, Nagasaki, Japan, ²Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁴Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁶Departments of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁷Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁸Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ⁹Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ¹⁰Department of Radiology and Radiation Research, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ¹¹Sasebo City General Hospital, Sasebo, Nagasaki, Japan
Background/Purpose: In the articles describing the 2010 rheumatoid arthritis (RA) classification criteria , it is stated that additional evidence of joint injury from imaging techniques such…
Abstract Number: 870 • 2013 ACR/ARHP Annual Meeting
How To Predict That Early Arthritis Without Rheumatoid Factor and ACPA Becomes Rheumatoid Arthritis According To ACR/EULAR 2010 After a 3-Years Follow-Up? Results From The Espoir Cohort
Gaël Mouterde¹, Cédric Lukas², Nathalie Rincheval³, Alain Saraux⁴, Philippe Dieude⁵ and Bernard Combe⁶, ¹Rheumatology, Montpellier 1 University, Lapeyronie Hospital, Montpellier, France, ²Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ³Institut Universitaire de Recherche Clinique, Montpellier, France, ⁴Department of rheumatology and unit of immunology (EA 2216), CHU Brest et Université Bretagne Occidentale, Brest, France, ⁵Rheumatology, Rheumatology departement & INSERM U699, Paris Diderot university, APHP, Bichat hospital, Paris, France, ⁶Rheumatology, Lapeyronie Hospital, Montpellier I university, Montpellier, France
Background/Purpose: To describe disease course of patients without rheumatoid factor (RF) and anti-citrullinated protein auto-antibodies (ACPA) in an inception cohort of early arthritis patients. To determine…
Abstract Number: 1962 • 2013 ACR/ARHP Annual Meeting
The Value Of the 2010 ACR/EULAR Rheumatoid Arthritis Classification Criteria For The Prognosis Of Early Arthritis: Evaluation Of Erosion Development With Ultrasonography
Nevsun Inanc¹, Fatma Alibaz-Oner², Meryem Can³, Pamir Atagündüz² and Haner Direskeneli², ¹Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ²Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ³Department of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: The 2010 ACR/EULAR Rheumatoid Arthritis(RA) classification criteria was developed to diagnose the early arthritis patients who will progress destructive disease and to start early…
Abstract Number: 833 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Diseases In Rheumatoid Arthritis: Can Early Treatment With Disease-Modifying Antirheumatic Drugs Alter The Risk?
Rishi Desai¹, Jaya Rao², Richard Hansen³, Gang Fang⁴, Matthew Maciejewski⁵ and Joel Farley⁴, ¹Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ²Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, ³Harrison School of Pharmacy, Auburn University, Auburn, AL, ⁴University of North Carolina, Chapel Hill, NC, ⁵Duke University, Durham, NC
Background/Purpose: Atherosclerosis is known to be accelerated in rheumatoid arthritis (RA) patients resulting in an increased cardiovascular (CV) risk. Structural damage to joints occurs aggressively…
Abstract Number: 1820 • 2013 ACR/ARHP Annual Meeting
Assessing 24-Hour Physical (In)Activity and Sleep In People With Early Rheumatoid Arthritis
Christopher Feehan¹, Eric C. Sayre², Erin Carruthers² and Lynne M. Feehan³, ¹Medicine, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Physical Therapy, Arthritis Research Centre of Canada and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: For people with inflammatory arthritis, the health benefits of physical activity (PA) and negative impact of sedentary lifestyle are clear. However, it is unclear…
Abstract Number: 799 • 2013 ACR/ARHP Annual Meeting
Clinical and Radiological Outcomes Of Two Years Remission Steered Treatment In Early Arthritis Patients
L. Heimans¹, K.V.C. Wevers-de Boer¹, G. Akdemir¹, H.K Ronday², T.H.E. Molenaar³, J. H. L. M. Van Groenendael⁴, A.J. Peeters⁵, I. Speyer⁶, G. Collee⁷, P.B. de Sonnaville⁸, B.A. Grillet⁹, T.W.J. Huizinga¹ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Haga Hospital, The Hague, Netherlands, ³Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁴Franciscus Hospital, Roosendaal, Netherlands, ⁵Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, ⁶Rheumatology, Bronovo Hospital, Den Haag, Netherlands, ⁷MCH, The Hague, Netherlands, ⁸Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, ⁹Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands
Background/Purpose: To evaluate outcomes after 2 years of remission steered therapy in early arthritis patients. Methods: 610 patients with early rheumatoid or undifferentiated arthritis (UA)…
Abstract Number: 1789 • 2013 ACR/ARHP Annual Meeting
In Early Rheumatoid Arthritis, The 12 Individual Biomarkers That Comprise The Multiple Biomarker Disease Activity Score Relate Differentially To Clinical Response and Radiographic Progression: Results From a Randomized Trial
Karen Hambardzumyan¹, Saedis Saevarsdottir², Rebecca Bolce³, Kristina Forslind⁴, Sofia Ernestam⁵, Ingemar F. Petersson⁶, Pierre Geborek⁷, David Chernoff³, Douglas J. Haney³, Eric H. Sasso³ and Ronald F van Vollenhoven⁸, ¹ClinTRID, the Karolinska Institute, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Crescendo Bioscience Inc., South San Francisco, CA, ⁴Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, ⁵Huddinge Hospital, Karolinska University Hospital, Huddinge, Sweden, ⁶Lund University, Lund, Sweden, ⁷Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁸ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: In early rheumatoid arthritis (eRA), clinical and radiographic predictors would be very useful for optimizing available therapies. Individual biomarkers and their combinations, such as…
Abstract Number: 710 • 2013 ACR/ARHP Annual Meeting
Interleukin-6 Driven STAT3 Phosphorylation In Circulating Lymphocytes Is Specific For CD4⁺ T Cells In Early Rheumatoid Arthritis
Amy E. Anderson¹, Christine Routledge¹, Philip Mawson², John D. Isaacs³ and Arthur G. Pratt³, ¹Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ²Musculoskeletal Directorate, The Freeman Hospital, Newcastle upon Tyne, United Kingdom, ³Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory autoimmune disease, caused by a breakdown in self tolerance. Robust biomarkers are needed which, as well having…
Abstract Number: 1771 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness Of Different Treatment Sequences Including Adalimumab In The Treat-To-Target Framework For Early Rheumatoid Arthritis In Germany
Malte Wolff¹, Zheng-Yi Zhou², James Signorovitch², James W. Shaw³ and Arijit Ganguli³, ¹AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ²Analysis Group, Inc., Boston, MA, ³AbbVie Inc., North Chicago, IL
Background/Purpose: The 2012 German rheumatoid arthritis (RA) treatment guidelines recommend sequential use of disease-modifying antirheumatic drugs (DMARDs) in a treat-to-target (T2T) framework. Biologics are recommended…
Abstract Number: 502 • 2013 ACR/ARHP Annual Meeting
Early Introduction Of Biologic Treatment Is An Important Predictor Of Sustained Favorable Outcome Including Clinical Remission In Early Arthritis But Not Of Sustained Favorable Outcome On Structure and Function Only: Results From The Espoir Cohort
Cécile Gaujoux-Viala¹, Laure Gossec², Maxime Dougados³, Francis Guillemin⁴ and Bruno Fautrel⁵, ¹EA 2415, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France, ²Rheumatology, Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France, ³Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁴CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁵Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France
Background/Purpose: The relevant elements to evaluate health states in RA should include remission, good functional ability and structural stability [1]. The concept of favorable outcome…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].